Floatz logo

Tucatinib

Metastatic Breast Cancer ( HER2 Negative)

Institut CurieSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Metastatic Breast Cancer ( HER2 Negative) cohort.

Asset / SponsorPhaseRating
ERIBULIN MONOMETHANESULFONATE
Eisai Inc.
Phase 2B
Ivonescimab
Fudan University
Phase 2CCC
Sacituzumab Tirumotecan
Fudan University
Phase 2CCC
TRASTUZUMAB
Institut Curie
Phase 2CCC
Datopotamab Deruxtecan
Fudan University
Phase 2CCC

Same molecule, other indications

Tucatinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
invasive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →